 |
Previous Article | Next Article 
The Journal of Neuroscience, November 15, 1999, 19(22):9813-9820
Neuronal Death and Blood-Brain Barrier Breakdown after
Excitotoxic Injury Are Independent Processes
Zu-lin
Chen1, 2,
Justin
A.
Indyk1, 2, 3,
Thomas H.
Bugge4,
Keith W.
Kombrinck4,
Jay L.
Degen4, and
Sidney
Strickland1, 2
1 Department of Pharmacology, 2 Program in
Genetics, and 3 Medical Scientist Training Program,
University at Stony Brook, Stony Brook, New York 11794-8651, and
4 Division of Developmental Biology, Children's Hospital
Research Foundation, Cincinnati, Ohio 45229
 |
ABSTRACT |
Neuronal damage in the CNS after excitotoxic injury is correlated
with blood-brain barrier (BBB) breakdown. We have used a glutamate
analog injection model and genetically altered mice to investigate the
relationship between these two processes in the hippocampus. Our
results show that BBB dysfunction occurs too late to initiate
neurodegeneration. In addition, plasma infused directly into the
hippocampus is not toxic and does not affect excitotoxin-induced neuronal death. To test plasma protein
recruitment in neuronal degeneration, we used plasminogen-deficient
(plg / ) mice, which are resistant to
excitotoxin-induced degeneration. Plasminogen is produced in the
hippocampus and is also present at high levels in plasma, allowing us
to determine the contribution of each source to cell death.
Intrahippocampal delivery of plasminogen to plg /
mice restored degeneration to wild-type levels, but intravenous delivery of plasminogen did not. Finally, although the neurons in
plg / mice do not die after excitotoxin
injection, BBB breakdown occurs to a similar extent as in wild-type
mice, indicating that neuronal death is not necessary for BBB
breakdown. These results indicate that excitotoxin-induced neuronal
death and BBB breakdown are separable events in the hippocampus.
Key words:
plasminogen; tPA; neurodegeneration; blood-brain
barrier; kainate; hippocampus; mouse
 |
INTRODUCTION |
Neuronal cell death is a hallmark of
many neurodegenerative disorders, such as Alzheimer's disease,
Parkinson's disease, and Huntington's disease. Loss of brain function
caused by neurodegeneration affects millions of people each year and is
a major cause of long-lasting disability. Despite the enormity of the
problem, the few therapies that attempt to retard the progression of
neurodegeneration in those disorders are not very effective (Shoulson,
1998 ). Therefore, a better understanding of the mechanisms of
neurodegeneration is a critically important medical issue.
Recent studies on the mechanisms of neurodegeneration have revealed
that neuronal death is often initiated by overexcitation of neurons
because of the extracellular accumulation of high levels of the
excitatory amino acid glutamate (Meldrum and Garthwaite, 1990 ; Coyle
and Puttfarcken, 1993 ; Lipton and Rosenberg, 1994 ). This mechanism for
neurodegeneration has been termed excitotoxicity. Consistent with this
concept, injection of glutamate receptor agonists, such as kainate
(KA), into the CNS induces neurodegeneration similar to
that seen in various neurodegenerative pathologies (Coyle et al.,
1978 ).
The downstream mechanisms of excitotoxic neurodegeneration are complex,
and many factors may contribute. One process that is associated with
cell death after ischemic stroke or epilepsy is the breakdown of the
blood-brain barrier (BBB), which allows plasma proteins to leak into
the brain parenchyma (Ting et al., 1986 ; Duncan and Todd, 1991 ).
Although there is a good correlation between neuronal degeneration and
BBB breakdown, it has not been determined whether either process is
dependent on the other. That is, does neuronal death require BBB
breakdown, or conversely, does neuronal death significantly contribute
to leakage of plasma proteins?
To address this question, we have used various approaches. Our results
indicate that neuronal death and BBB breakdown are independent of each
other. This work has implications for the treatment of
neurodegenerative disorders and other CNS pathologies.
 |
MATERIALS AND METHODS |
Intrahippocampal injections. Adult male wild-type
mice, tissue plasminogen activator (tPA)-deficient
(tPA / ) mice (Carmeliet et al., 1994 ),
plasminogen-deficient (plg / ) mice
(Bugge et al., 1995 ), or plasminogen-heterozygous
(plg+/ ) mice (Bugge et al., 1995 ) were
injected intraperitoneally with atropine (0.6 mg/kg of body weight) and
then were anesthetized deeply with 2.5% avertin (0.02 ml/gm of body
weight). They were placed in a stereotaxic apparatus and injected
unilaterally with 1.5 or 0.5 nmol of kainate (Sigma, St. Louis, MO or
Alexis, San Diego, CA) in 0.3 µl of PBS into the hippocampus
(Andersson et al., 1991 ; Tsirka et al., 1995 ). After variable lengths
of time, the animals were anesthetized and perfused through the heart
with ice-cold PBS, followed by 4% paraformaldehyde in 0.1 M PBS. The brains were removed, post-fixed in the
same fixative overnight at 4°C, and then left in 30% sucrose in PBS
for 48 hr at 4°C. Coronal brain sections (30 µm) were cut on a
microtome, collected in 10 mM PBS, and then
processed for cresyl violet staining and immunohistochemistry. For
cresyl violet staining, the sections were mounted onto slides,
dehydrated, and then stained with cresyl violet, which stains rough
endoplasmic reticulum in neuronal cell bodies.
Intrahippocampal infusions. To obtain autologous plasma for
infusion, ~200 µl of blood was collected from the femoral vein under anesthesia and immediately centrifuged at 7000 rpm for 5 min at
4°C. The plasma samples were stored at 70°C, recentrifuged, and
diluted 1:1 in PBS before use. The mice were allowed to recover for 1 week before intrahippocampal infusion. Plasminogen was purified from
human plasma (Deutsch and Mertz, 1970 ) and characterized by SDS-PAGE
and casein zymography (data not shown). For the infusion, plg / or wild-type mice were
anesthetized as above and placed in a stereotaxic apparatus, and a
micro-osmotic pump (Alza, Palo Alto, CA) containing 100 µl of PBS
(for three wild-type and three plg /
control mice infusion), 100 µl of 1 mg/ml human plasminogen in PBS
(for four plg / mice infusion), or 100 µl of autologous plasma (for six wild-type mice infusion) was placed
subcutaneously on the back of the animals. A brain infusion cannula
connected to the pump was positioned at coordinates bregma 2.5 mm,
mediolateral 0.5 mm, and dorsoventral 1.6 mm to deliver the compound
near the midline. The infusion rate was 0.5 µl/hr. The pump was
allowed to infuse the designated solution for 2 d, and kainate or
PBS (for control) was then injected as described above. One or 2 d
after kainate injection, the mice were killed, and their brains
were examined for neuronal degeneration and processed for immunohistochemistry.
Intravenous injections. For intravenous injection,
plg / mice were anesthetized with
avertin, and their right side femoral vein was exposed and injected
with 0.2 ml of 5 mg/ml human plasminogen solution (plasminogen purified
as described above; n = 4). In control animals
(n = 3), 0.2 ml of vehicle (PBS) was injected. Within
15 min, kainate was injected. At 0.5, 2, 8, and 24 hr after intravenous
plasminogen injection, blood samples were collected from the tails and
mixed with an equal volume of 250 mM sodium citrate, and plasma was prepared by centrifugation at 7000 rpm for 5 min.
Zymography. Five microliters of each plasma sample
(prepared as above) or 0.7 µg of human plasminogen was
electrophoresed on a 10% SDS- polyacrylamide gel. After
electrophoresis, the gel was washed in 2.5% Triton X-100 for 20 min,
followed by three rinses of 10 min each in water. The gel was overlaid
on a substrate composed of 2.5% nonfat milk, 0.1 M Tris, 1% low-melting point agarose, 0.1%
sodium azide, 2.25 mg/ml protein from mouse hippocampal extract (as a
source of mouse tPA) (Sappino et al., 1993 ), and 1 mM amiloride (an inhibitor of urokinase-type
plasminogen activator) (Vassali and Belin, 1987 ). The gel with the
substrate underlay was then incubated at 37°C in a humid chamber for
24-48 hr and photographed.
Immunohistochemistry. Mouse brain sections, manipulated as
described above, were incubated with affinity-purified rabbit
anti-mouse laminin polyclonal antibody (Sigma) at 1:1000 dilution or
goat anti-human plasminogen antibody (Sigma) at 1:100 dilution at 4°C overnight. Biotinylated secondary antibodies were used at 1:200 dilution (Vector Laboratories, Burlingame, CA), and the
avidin-biotin-peroxidase complex (ABC reaction) was visualized with
diaminobenzidine and hydrogen peroxide. For IgG extravasation
detection, brain sections were incubated with biotinylated goat
anti-mouse IgG antibody (Vector Laboratories) at 1:200 dilution and
visualized as described above. After anti-mouse IgG staining, some
brain sections were counterstained with cresyl violet.
Quantitation of neuronal loss in the hippocampus.
Plg / mice were infused into the
hippocampus with PBS (n = 3) or human plasminogen (n = 4), or injected intravenously with PBS
(n = 3) or human plasminogen (n = 4)
and then injected with kainate (1.5 nmol). As control, plg+/ mice were also injected with
kainate. For autologous plasma experiments, wild-type mice were infused
with autologous plasma (n = 6) or PBS
(n = 3) and then injected with kainate (0.5 nmol; three
PBS-infused and three plasma-infused mice) or PBS (three plasma-infused
mice). Their brains were processed as above, and serial sections of 30 µm were cut and stained with cresyl violet. Given the dramatic neuronal loss in the hippocampus in these experiments, we used camera
lucida tracings to quantitate the number of neurons remaining (Tsirka
et al., 1995 , 1997 ). Four sections from the hippocampus of each mouse
in each group were matched, and the linear lengths of dead pyramidal
cell layers were determined on each section. The lengths were
quantitated from camera lucida drawings of the hippocampus. The values
for each category were averaged across the subjects in a group using
the SigmaPlot program (Jandel Scientific, Corte Madera, CA).
 |
RESULTS |
BBB leakage after kainate injection occurs too late to initiate
neurodegeneration and laminin degradation
As a first test of the role of BBB breakdown in hippocampal
neuronal death, we examined the time course of plasma protein leakage
after kainate injection in wild-type mice using IgG extravasation as an
indicator. IgG is present at high levels in plasma (550-1900 mg/dl)
and is easy to detect. For these reasons, the presence of IgG in the
brain parenchyma has been used to monitor protein extravasation and
disruption of the BBB (Ruth and Feinerman, 1988 ). At 4, 8, and 24 hr
after intrahippocampal kainate injection, mice were transcardially
perfused, and their brains were stained for mouse IgG. At 4 hr, there
was no detectable IgG leakage into the CA1 region of the hippocampus
(Fig. 1A). However,
laminin immunostaining, the loss of which is correlated with neuronal
death (Chen and Strickland, 1997 ), was considerably decreased (Fig.
1B). At 8 hr, IgG leakage was still not detectable in
the CA1 region (Fig. 1C), but the CA1 pyramidal neurons in
the kainate-injected side exhibited pyknotic morphology characteristic
of cell death (Fig. 1G), and laminin immunostaining remained
approximately the same as at 4 hr in the kainate-injected side (Fig.
1D). At 24 hr, IgG leakage was dramatically increased
(Fig. 1E), and again laminin staining was similar as
at the 4 hr time point (Fig.
1B,F). One possibility was
that this breakdown might be a consequence of neuronal degeneration,
because it occurs after neurons in the kainate-injected side are
undergoing degeneration (Fig.
1G,E,H). However,
experiments shown below argue against this interpretation.

View larger version (116K):
[in this window]
[in a new window]
|
Figure 1.
BBB breakdown after kainate injection occurs after
the initiation of neurodegeneration and laminin degradation. Wild-type
mice were unilaterally injected with kainate (1.5 nmol) and killed at
the indicated time points, and brain sections were stained for mouse
IgG with light cresyl violet counterstaining (A,
C, E) or anti-laminin immunostaining
(B, D, F). Higher
magnification of the boxed areas in C and
E are shown in G and H,
respectively. At 4 and 8 hr after kainate injection, plasma proteins as
indicated by IgG immunostaining (arrowheads indicate
IgG-stained areas in A and C) have not
yet leaked into the CA1 region of the hippocampus (A,
C, G), but laminin is already degraded
(B, D) and the neurons are dying
(G). The color difference between
G and H is a result of the increased IgG
staining in H. IgG+CV,
Anti-mouse IgG immunostaining counterstained lightly with cresyl
violet; LN, anti-laminin immunostaining;
arrows, kainate injection sites;
arrowheads, anti-mouse IgG positively stained areas.
Scale bars: A-F, 1 mm; G,
H, 50 µm.
|
|
Because BBB dysfunction is not detectable in the hippocampal CA1 region
until significant neuronal degeneration has already ensued, BBB
breakdown appears to occur too late to be an initiator of neuronal damage.
Plasma infused into the hippocampus is not toxic and does not
affect excitotoxin-induced neuronal death
Although the staining for IgG suggested that plasma proteins were
not initiating neuronal degeneration, it was possible that concentrations too low to be detected by immunostaining were playing a
role. To test this possibility, blood was collected from a mouse, plasma was prepared, and the autologous plasma was infused into the
hippocampus of the same mouse, with or without an accompanying submaximal kainate injection. If plasma proteins are neurotoxic by
themselves, there should be some signs of neuronal damage without kainate injection. Likewise, if plasma proteins can exacerbate excitotoxin-induced neurodegeneration, kainate injection should promote
more neurodegeneration when compared with control mice. However, our
results showed that plasma infusion was not toxic to hippocampal
neurons (Fig.
2A,C,E-G;
Table 1) and that previous infusion of
autologous plasma did not exacerbate or attenuate kainate-induced
neuronal death (Fig. 2B,D; Table
1). This result shows that plasma is not toxic to hippocampal neurons
and further suggests that BBB breakdown is not a major factor in
excitotoxic cell death.

View larger version (95K):
[in this window]
[in a new window]
|
Figure 2.
Autologous plasma is not toxic to hippocampal
neurons and does not affect kainate-induced neuronal degeneration.
Wild-type mice were infused with PBS or autologous plasma for 2 d,
and then PBS or kainate (0.5 nmol) was injected unilaterally as
indicated. Two days after kainate injection, the mice were killed, and
brain sections were stained with cresyl violet
(A-D) or anti-mouse IgG immunostaining with
cresyl violet counterstaining (E).
Intrahippocampal infusion of plasma does not cause neurodegeneration
(compare C, A) and also does not affect
kainate-induced neurodegeneration (compare D,
B). The plasma infusions were efficient, as indicated by
the brown color of the IgG staining
(E). Higher magnification of the
boxed areas in E are shown in
F and G. The neurons in the most
efficiently infused area (F) show no detectable
morphological changes when compared with those in less efficiently
infused area (G). The brown
staining in F is contributed by high concentration
of IgG accumulated in this area, which indicates the efficiency of
plasma protein diffusion. The IgG concentration in the area shown in
G is very low and appears only as weak background color.
CV, Cresyl violet staining;
IgG+CV, anti-mouse IgG immunostaining
with cresyl violet counterstaining. Scale bars: A-E, 1 mm; F, G, 50 µm.
|
|
View this table:
[in this window]
[in a new window]
|
Table 1.
The effect of autologus plasma intracerebral infusion on
neuronal viability and sensitivity to kainate in wild-type mice
|
|
Intrahippocampal infusion of plasminogen rescues neuronal
sensitivity to excitotoxin-induced degeneration in
plg / mice
An extracellular protease cascade involving tPA and plasmin
participates in excitotoxin-induced neurodegeneration (Tsirka et al.,
1995 , 1997 ; Strickland et al., 1996 ; Wang et al., 1998 ). In this model
of degeneration, excess neuronal depolarization increases the release
and synthesis of tPA in the hippocampus (Qian et al., 1993 ; Gualandris
et al., 1996 ; Parmer et al., 1997 ; Baranes et al., 1998 ). This protease
activates plasminogen to plasmin (Tsirka et al., 1997 ), which then
initiates laminin degradation (Chen and Strickland, 1997 ). Loss of
laminin-mediated interaction destabilizes neurons and is an important
factor in promoting neuronal cell death. Pharmacological blockade of
plasmin or genetic deficiency in either tPA or plasminogen makes mice
resistant to neuronal cell death (Tsirka et al., 1995 , 1997 ; Chen and
Strickland, 1997 ).
Plasminogen is a serum protease whose primary role is fibrinolysis
(Bugge et al., 1996 ). It is present at high levels in the blood (~13
mg/dl) (Lijnen et al., 1996 ) and is also synthesized by hippocampal
neurons (Tsirka et al., 1997 ) in which its mRNA and protein levels are
increased after kainate injection (Tsirka et al., 1997 ; Matsuoka et
al., 1998 ). Excitotoxin injection causes BBB dysfunction (Saija et al.,
1992 ; Bolton and Perry, 1998 ), resulting in leakage of plasma proteins
into the brain parenchyma that might contribute to neuronal damage
(Ruth, 1986 ). Therefore, the plasminogen needed to promote neuronal
excitotoxic death in the hippocampus could be derived from local CNS
synthesis or from extravasation through a compromised BBB.
We investigated this question by using
plg / mice (Bugge et al., 1995 ; Ploplis
et al., 1995 ), which are viable and whose neurons are resistant to
excitotoxin-induced neuronal death (Tsirka et al., 1997 ). The
experimental strategy was to reconstitute CNS or vascular sources of
plasminogen, through either intrahippocampal infusion or
intravenous injection, respectively. For intrahippocampal infusion, plasminogen was infused for 2 d before kainate was
injected into the hippocampus. The infusion was then continued for an
additional 24 hr, and neuronal degeneration was determined. For
intravenous injection, a bolus of plasminogen was injected just before
hippocampal injection of kainate. After 24 hr, neuronal degeneration
was determined. The extent of degeneration in these two protocols would
reveal the relative contribution of CNS and vascular plasminogen to
excitotoxin-induced neuronal death.
To obtain sufficient quantities of plasminogen, human plasma was used
for protein purification. By zymographic assay, we found that mouse tPA
could efficiently activate human plasminogen (Fig. 3, lanes 1, 2).

View larger version (57K):
[in this window]
[in a new window]
|
Figure 3.
Zymographic analysis of the activation of human
plasminogen by mouse tPA. Wild-type mouse blood and a sample of human
plasminogen were assayed for activation by mouse tPA. The amount of
mouse plasminogen in lane 1 was ~0.3 µg, and the
amount of human plasminogen in lane 2 was ~0.7 µg.
Mouse tPA activated both samples of plasminogen showing that the human
protein is a substrate for mouse tPA. In addition, plasma was collected
from plg / mice before or after intravenous
plasminogen injection at the indicated time points. The plasminogen
activity in the samples was visualized as described in Materials
and Methods. There is no detectable plasminogen activity in
plg / mice before injection (lane
3), but it is present at concentrations greater or equal to
that of wild-type mice until 8 hr after injection (compare lanes
4-6 with lane 1). Protein molecular weight
standards are indicated to the left.
|
|
To determine whether the kainate-resistant phenotype of
plg / mice could be rescued by
intrahippocampal infusion of plasminogen, either PBS or plasminogen was
infused into the hippocampus of plg /
mice, and then kainate was injected. Their brains were then examined for neurodegeneration. The PBS-infused mice showed resistance to
neuronal cell death, consistent with previous observations (Tsirka et
al., 1997 ) (Fig. 4A;
Table 2). In contrast,
plasminogen-infused mice exhibited dramatically increased neuronal
degeneration (Fig. 4C; Table 2). Furthermore, in PBS-infused
plg / mice, hippocampal laminin
immunostaining was almost intact (Fig. 4B), whereas
in plasminogen-infused mice, it was dramatically decreased (Fig.
4D). Therefore, the resistance of
plg / mice to excitotoxin-induced
neurodegeneration can be rescued by local plasminogen reconstitution.
This result also demonstrates that human plasminogen can be efficiently
activated by murine tPA in vivo. To determine the extent of
plasminogen infusion, brain sections were stained with anti-plasminogen
antibody. This staining showed that the infused plasminogen diffused
efficiently to both sides of the hippocampus (Fig.
4E), but neuronal degeneration occurs only on the
kainate-injected side (Fig. 4C), indicating that plasminogen
is not toxic by itself.

View larger version (93K):
[in this window]
[in a new window]
|
Figure 4.
Intrahippocampal infusion of plasminogen restores
neuronal sensitivity of plg / mice to
excitotoxin. Coronal brain sections through the hippocampus of
plg / mice treated as indicated in each panel
were stained using cresyl violet (A, C),
anti-laminin immunostaining (B, D), or
anti-plasminogen immunostaining (E). PBS-infused
mice were resistant to kainate-induced neurodegeneration
(A) and laminin degradation
(B), but plasminogen-infused mice were sensitive
to neurodegeneration and laminin degradation. The efficiency of
plasminogen infusion was shown by plasminogen antibody immunostaining
(brown in E). CV, Cresyl
violet staining; LN, laminin immunostaining;
Plg, plasminogen immunostaining; arrows,
kainate injection sites; arrowheads, PBS or plasminogen
infusion sites. The dotted area in E
indicates the boundary of plasminogen diffusion. Scale bar, 1 mm.
|
|
View this table:
[in this window]
[in a new window]
|
Table 2.
The effect of exogenous administration of plasminogen on
neuronal sensitivity to excitotoxin in plg / mice
|
|
Intravenous injection of plasminogen into
plg / mice does not restore neuronal sensitivity
to excitotoxin
To determine whether vascular plasminogen derived from BBB
disruption could also contribute to excitotoxin-induced
neurodegeneration, we injected plasminogen intravenously into
plg / mice to reconstitute the vascular
source of plasminogen. Previous results showed that intravenous
injection of 1 mg of plasminogen is sufficient to restore thrombolytic
potential in plg / mice (Lijnen et al.,
1996 ). We therefore used this dose in our experiments. Within 15 min of
intravenous PBS (control) or plasminogen injection, the mice were
intrahippocampally injected with kainate. One day later, the brains
were processed to determine neurodegeneration. Plg / mice injected intravenously with
buffer (Fig. 5A) or
plasminogen (Fig. 5C) both showed no significant hippocampal
neuronal loss (Table 2), and laminin expression showed minimal changes
in both groups of mice (Fig. 5B,D),
indicating that intravenous plasminogen cannot restore the wild-type
phenotype.

View larger version (66K):
[in this window]
[in a new window]
|
Figure 5.
Intravenous bolus injection of human plasminogen
does not restore neuronal sensitivity of plg /
mice to excitotoxin. Cresyl violet (A, C)
or anti-laminin immunostained (B, D)
coronal brain sections through the hippocampus of PBS
(A, B) or plasminogen (C,
D) intravenously injected plg /
mice 24 hr after kainate injection. Both groups of mice are resistant
to neurodegeneration and laminin degradation. CV, Cresyl
violet staining; LN, anti-laminin immunostaining;
arrows, kainate injection sites. Scale bar, 1 mm.
|
|
One reason that the intravenous plasminogen injection did not promote
hippocampal neurodegeneration could be because of subthreshold levels
of plasminogen in the blood after intravenous injection. In this case,
even if the BBB was compromised, there would not be sufficient plasmin
activity to catalyze hippocampal laminin degradation and promote
neuronal death. Therefore, we obtained blood samples from
plg / mice at various time points after
intravenous plasminogen injection and analyzed blood plasminogen levels
by zymography. After intravenous plasminogen injection,
plg / mice showed a higher blood
plasmin activity at 30 min, 2 hr, and 8 hr than that present in
wild-type mice (Fig. 3) when activated by mouse tPA. This result shows
that intravenous injection of plasminogen is sufficient to restore
wild-type blood levels for at least 8 hr. Previous studies showed that
laminin degradation, a hallmark of kainate-induced neurodegeneration,
occurs within 2 hr of excitotoxin injection (Chen and Strickland,
1997 ). Therefore, these results indicate that leakage of vascular
plasminogen into the CNS via BBB dysfunction is not a critical factor
in excitotoxic neurodegeneration.
BBB breakdown occurs after kainate injection in
tPA / or plg / mice in the
absence of neuronal death
The above results showed that BBB breakdown is not a critical
factor in promoting neuronal death during excitotoxic injury and occurs
after the initiation of laminin degradation and neurodegeneration. These results raise the possibility that BBB breakdown could be a
consequence of neurodegeneration or a parallel pathological change. To
address this question, we analyzed BBB breakdown after kainate
injection in tPA / or
plg / mice, whose neurons are resistant
to degeneration (Tsirka et al., 1995 , 1997 ). Although the neurons in
tPA / or
plg / mice are resistant to
degeneration after kainate injection (Fig. 6 compare
B,D with F), BBB
breakdown occurred to a similar extent as in wild-type mice (Fig.
6A,C,E). This result
indicates that BBB breakdown is not a direct consequence of
neurodegeneration. Because BBB breakdown occurs after kainate injection
in tPA / or
plg / mice but the neurons are spared,
this result suggests neuronal death during acute excitotoxic injury is
not required for BBB breakdown.

View larger version (100K):
[in this window]
[in a new window]
|
Figure 6.
BBB breakdown occurs in the absence of neuronal
death after kainate injection in tPA / or
plg / mice. Coronal brain sections through the
hippocampus of tPA / ,
plg / , or wild-type mice 2 d after kainate
injection were stained with anti-mouse IgG antibody (A,
C, E) or cresyl violet (B,
D, F). BBB breakdown after kainate
injection is equivalent in tPA / ,
plg / , or wild-type mice as evidenced by
anti-mouse IgG staining (diffuse dark area in ipsilateral side, marked
by arrowheads in A, C,
E), whereas the tPA / and
plg / neurons are resistant to degeneration
(compare B, D with
F). CV, Cresyl violet staining;
IgG, anti-mouse IgG immunostaining;
arrows, kainate injection sites;
arrowheads, anti-mouse IgG positively stained areas.
Scale bar, 1 mm.
|
|
 |
DISCUSSION |
Various pathologies can affect BBB function, including brain
tumors (Roelcke et al., 1995 ), bacterial meningitis (Paul et al.,
1998 ), and multiple sclerosis (Kwon and Prineas, 1994 ). One dramatic
example is the brain edema that results from cerebral ischemia (Wahl et
al., 1990 ; Preston et al., 1993 ) and excitotoxic injury (Lassmann et
al., 1984 ; Seitelberger et al., 1990 ). Although BBB dysfunction has
long been associated with neuronal damage after excitotoxic injury
(Ruth, 1986 ; Ting et al., 1986 ), a direct connection between these two
events has not been established (Rapaport and Thompson, 1975 ; Kuroiwa
et al., 1985 ; Bolton and Perry, 1998 ). For example, Bolton and Perry
(1998) found that, although juvenile animals exhibited greater BBB
breakdown after excitotoxin injection, lesion size and number of
infiltrating leukocytes were similar when compared with the adult.
Moreover, Rapaport and Thompson (1975) found that osmotic opening of
BBB did not cause neurological deficits in monkey.
One direct consequence of BBB breakdown is plasma protein leakage into
the brain parenchyma, which may cause edema, but the effect of this
leakage on neurons and other CNS cells also remains an open question
(Ikuta et al., 1983 ; Strosznajder et al., 1983 ; Ruth, 1986 ; Ting et
al., 1986 ; Saija et al., 1992 ). Edema fluid has homeostatic properties
(Ikuta et al., 1983 ), and albumin, a major plasma protein, can
stimulate the incorporation of free arachidonic acid into brain
phospholipids (Strosznajder et al., 1983 ) and therefore reduce
neurotoxic free radical levels in the brain parenchyma. These findings
argue against a direct acute contribution of BBB breakdown to
neurodegeneration and neurotoxicity.
In our studies, we initially used two approaches to investigate the
role of BBB breakdown in acute excitotoxicity. First, we compared the
time course of plasma protein leakage and neuronal death after
excitotoxin injection. These studies showed that the first significant
BBB leakage occurs after neuronal death has already been initiated,
which suggested that plasma proteins do not initiate the degeneration.
Previously, a temporal analysis during transient focal ischemia showed
that neuronal damage precedes BBB leakage; the authors of that study
concluded that BBB dysfunction is unlikely to contribute to neuronal
death (Albayrak et al., 1997 ).
Second, we directly infused plasma proteins into the brain parenchyma
and showed that they are not toxic nor do they affect excitotoxin-induced death. To our knowledge, plasma has not been examined previously for its direct neurotoxic effects or its ability to
modulate excitotoxic damage. However, autologous serum and rat albumin
have been injected into the rat brain and neurotoxicity was observed
(Hassel et al., 1994 ; Kadota et al., 1997 ). The difference in results
between these studies and ours could be caused by a difference in
protocols. Whereas we infused plasma at a rate of 0.5 µl/hr for
4 d, the previous studies injected a 25 µl volume of serum or
albumin into the rat brain in a shorter time (Hassel et al., 1994 ;
Kadota et al., 1997 ). It is possible that the large volume injection
coupled with increased fluid extravasation attributable to protein
osmotic effects could have contributed to edema-mediated neuronal death
in those studies.
Although these two analyses argue against a role for BBB breakdown in
neuronal death, there are caveats with this interpretation. In our time
course study of BBB breakdown, we cannot rule out the possibility that
undetectable amounts of plasma protein may be extravasating into the
brain parenchyma and promoting neuronal death. Also, in our direct
autologous plasma infusion experiment, the plasma protein may not be
promoting a toxic effect because our delivery may not adequately mimic
the accumulation that occurs after BBB breakdown.
Both of these caveats have been addressed by the use of the
plg / mice. Because plasminogen is
required for efficient excitotoxic killing and because the blood
normally contains very high concentrations of this protein, the source
of plasminogen could be leakage from the blood. Intrahippocampal
infusion of plasminogen restored kainate sensitivity in
plg / mice, whereas intravenous
injection of plasminogen did not. This result, which uses proteolytic
degradation of laminin and neuronal death as end points for the assay,
indicates that plasma-derived plasminogen cannot fulfill the
requirements for this protein in degeneration.
These analyses, coupled with previous evidence, argue that BBB
breakdown and plasma protein leakage into the brain parenchyma after
excitotoxic injury are not sufficient for neuronal death.
A second question concerns the mechanism of BBB breakdown. The
properties of the BBB are contributed by the specialized endothelial cells of the CNS capillaries and the end feet of astrocytes that wrap
the endothelial cells on the neuronal side. The endothelial cells of
the CNS capillaries are distinct from those in other organs in that
they are joined by tight junctions of high electric resistance, and
there is also no transcellular movement of compounds through the CNS
endothelial cells (Kandel et al., 1991 ; Bradbury, 1993 ). These
properties provide the critical barrier that restricts the passage of
vascular substances into the CNS.
Injection of glutamate analogs either systemically or intracerebrally
can cause BBB breakdown in some regions of the brain, such as the
hippocampus (Nitsch and Hubauer, 1986 ; Ruth, 1986 ; Ruth and Feinerman,
1988 ). This effect could be mediated on astrocytes and endothelial
cells indirectly via effects of the excitotoxin on neurons, e.g., the
neurons could release factors that influence astrocyte or endothelial
function. Alternatively, glutamate analogs could affect these cells directly.
Glutamate receptors have been reported to be present on CNS endothelial
cells and astrocytes (Steinhauser and Gallo, 1996 ; Krizbai et al.,
1998 ). There is other evidence that astrocyte function, which forms an
important functional component of BBB (Janzer and Raff, 1987 ), is
adversely affected by excitotoxins. During ischemic injury, astrocyte
interactions with the extracellular matrix are rapidly disrupted
(Wagner et al., 1997 ), and deficits in astrocytes result in incomplete
reconstruction of impaired BBB (Kakinuma et al., 1998 ). After kainate
injection, a loss of GFAP staining, a marker of astrocytes, coincides
with IgG extravasation (Bolton and Perry, 1998 ). An early massive
swelling of astrocyte processes after kainate injection also occurs
(Lassmann et al., 1986 ). The tight junctions of the CNS endothelial
cells do not seem to be affected by excitotoxins, but transendothelial
pinocytosis is increased by kainate injection (Nitsch and Hubauer,
1986 ). Therefore, astrocyte dysfunction coupled with increased
transendothelial pinocytosis in the endothelial cells may contribute to
BBB breakdown after excitotoxic injury.
To address this question, we analyzed BBB dysfunction in
tPA / or
plg / mice whose neurons are resistant
to death after kainate injection. Our result shows that they exhibit
BBB breakdown after kainate injection. These results argue that the
effect of kainate on the BBB is a direct result of effects on the
astrocytes and endothelium, and they show that neuronal death is not
required for BBB breakdown.
Pharmacological treatment of CNS pathologies is complicated by the
inaccessibility of the region to intravenously administered agents.
This problem has severely limited drug design and therapy into the CNS.
One way to circumvent this difficulty would be to combine systemic
treatments with a protocol that transiently opens the BBB. A concern of
this approach is that opening the BBB could be deleterious to neurons
in the CNS. However, our results indicate that in the absence of frank
edema, plasma proteins do not cause significant neurodegeneration in
the CNS, suggesting that the therapeutic strategy of opening the BBB
might be more promising than previously realized.
 |
FOOTNOTES |
Received June 15, 1999; revised Aug. 23, 1999; accepted Sept. 1, 1999.
This work was supported by Human Frontier Science Program Fellowship
LT0486 to Z.-L.C., National Institutes of Health Grants NS-35704 and
NS-38472, and American Cancer Society Grant CB205 to S.S. We are
grateful to Dr. Fernando Sallés for comments on this manuscript.
Z.-L.C. thanks all of the members of the Strickland laboratory for
their support.
Correspondence should be addressed to Sidney Strickland, Department of
Pharmacology, University at Stony Brook, Stony Brook, NY 11794-8651. E-mail: sid{at}pharm.sunysb.edu.
 |
REFERENCES |
-
Albayrak S,
Zhao Q,
Siesjo BK,
Smith ML
(1997)
Effect of transient focal ischemia on blood-brain barrier permeability in the rat: correlation to cell injury.
Acta Neuropathol (Berl)
94:158-163[Medline].
-
Andersson PB,
Perry VH,
Gordon S
(1991)
The kinetics and morphological characteristics of the macrophage-microglial response to kainic acid-induced neuronal degeneration.
Neuroscience
42:201-214[Web of Science][Medline].
-
Baranes D,
Lederfein D,
Huang YY,
Chen M,
Bailey CH,
Kandel ER
(1998)
Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway.
Neuron
21:813-825[Web of Science][Medline].
-
Bolton SJ,
Perry VH
(1998)
Differential blood-brain barrier breakdown and leucocyte recruitment following excitotoxic lesions in juvenile and adult rats.
Exp Neurol
154:231-240[Web of Science][Medline].
-
Bradbury MW
(1993)
The blood-brain barrier.
Exp Physiol
78:453-472[Web of Science][Medline].
-
Bugge TH,
Flick MJ,
Daugherty CC,
Degen JL
(1995)
Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction.
Genes Dev
9:794-807[Abstract/Free Full Text].
-
Bugge TH,
Kombrinck KW,
Flick MJ,
Daugherty CC,
Danton MJ,
Degen JL
(1996)
Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency.
Cell
87:709-719[Web of Science][Medline].
-
Carmeliet P,
Schoonjans L,
Kieckens L,
Ream B,
Degen J,
Bronson R,
De Vos R,
van den Oord JJ,
Collen D,
Mulligan RC
(1994)
Physiological consequences of loss of plasminogen activator gene function in mice.
Nature
368:419-424[Medline].
-
Chen ZL,
Strickland S
(1997)
Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin.
Cell
91:917-925[Web of Science][Medline].
-
Coyle JT,
Puttfarcken P
(1993)
Oxidative stress, glutamate, and neurodegenerative disorders.
Science
262:689-695[Abstract/Free Full Text].
-
Coyle JT,
Molliver ME,
Kuhar MJ
(1978)
In situ injection of kainic acid: a new method for selectively lesioning neural cell bodies while sparing axons of passage.
J Comp Neurol
180:301-323[Web of Science][Medline].
-
Deutsch DG,
Mertz ET
(1970)
Plasminogen: purification from human plasma by affinity chromatography.
Science
170:1095-1096[Abstract/Free Full Text].
-
Duncan R,
Todd N
(1991)
Epilepsy and the blood-brain barrier.
Br J Hosp Med
45:32-34[Medline].
-
Gualandris A,
Jones TE,
Strickland S,
Tsirka SE
(1996)
Membrane depolarization induces calcium-dependent secretion of tissue plasminogen activator.
J Neurosci
16:2220-2225[Abstract/Free Full Text].
-
Hassel B,
Iversen EG,
Fonnum F
(1994)
Neurotoxicity of albumin in vivo.
Neurosci Lett
167:29-32[Web of Science][Medline].
-
Ikuta F,
Yoshida Y,
Ohama E,
Oyanagi K,
Takeda S,
Yamazaki K,
Watabe K
(1983)
Revised pathophysiology on BBB damage: the edema as an ingeniously provided condition for cell motility and lesion repair.
Acta Neuropathol Suppl (Berl)
8:103-110[Medline].
-
Janzer RC,
Raff MC
(1987)
Astrocytes induce blood-brain barrier properties in endothelial cells.
Nature
325:253-257[Medline].
-
Kadota E,
Nonaka K,
Karasuno M,
Nishi K,
Teramura K,
Hashimoto S
(1997)
Neurotoxicity of serum components, comparison between CA1 and striatum.
Acta Neurochir Suppl (Wien)
70:141-143[Medline].
-
Kakinuma Y,
Hama H,
Sugiyama F,
Yagami K,
Goto K,
Murakami K,
Fukamizu A
(1998)
Impaired blood-brain barrier function in angiotensinogen-deficient mice.
Nat Med
4:1078-1080[Web of Science][Medline].
-
Kandel ER,
Schwartz JH,
Jessell TM
(1991)
In: Principles of neural science, pp 1054-1056. New York: Elsevier.
-
Krizbai IA,
Deli MA,
Pestenacz A,
Siklos L,
Szabo CA,
Andras I,
Joo F
(1998)
Expression of glutamate receptors on cultured cerebral endothelial cells.
J Neurosci Res
54:814-819[Web of Science][Medline].
-
Kuroiwa T,
Cahn R,
Juhler M,
Goping G,
Campbell G,
Klatzo I
(1985)
Role of extracellular proteins in the dynamics of vasogenic brain edema.
Acta Neuropathol
66:3-11[Medline].
-
Kwon EE,
Prineas JW
(1994)
Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study.
J Neuropathol Exp Neurol
53:625-636[Web of Science][Medline].
-
Lassmann H,
Petsche U,
Kitz K,
Baran H,
Sperk G,
Seitelberger F,
Hornykiewicz O
(1984)
The role of brain edema in epileptic brain damage induced by systemic kainic acid injection.
Neuroscience
13:691-704[Web of Science][Medline].
-
Lassmann H,
Baran H,
Petsche U,
Kitz K,
Sperk G,
Hornykiewicz O,
Seitelberger F
(1986)
Ultrastructural analysis of rat brain tissue following systemic kainate administration.
Adv Exp Med Biol
203:223-230[Medline].
-
Lijnen HR,
Carmeliet P,
Bouche A,
Moons L,
Ploplis VA,
Plow EF,
Collen D
(1996)
Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen.
Blood
88:870-876[Abstract/Free Full Text].
-
Lipton SA,
Rosenberg PA
(1994)
Excitatory amino acids as a final common pathway for neurologic disorders.
N Engl J Med
330:613-622[Free Full Text].
-
Matsuoka Y,
Kitamura Y,
Taniguchi T
(1998)
Induction of plasminogen in rat hippocampal pyramidal neurons by kainic acid.
Neurosci Lett
252:119-122[Medline].
-
Meldrum B,
Garthwaite J
(1990)
Excitatory amino acid neurotoxicity and neurodegenerative disease.
Trends Pharmacol Sci
11:379-387[Medline].
-
Nitsch C,
Hubauer H
(1986)
Distant blood-brain barrier opening in subfields of the rat hippocampus after intrastriatal injections of kainic acid but not ibotenic acid.
Neurosci Lett
64:53-58[Web of Science][Medline].
-
Parmer RJ,
Mahata M,
Mahata S,
Sebald MT,
O'Connor DT,
Miles LA
(1997)
Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA.
J Biol Chem
272:1976-1982[Abstract/Free Full Text].
-
Paul R,
Lorenzl S,
Koedel U,
Sporer B,
Vogel U,
Frosch M,
Pfister HW
(1998)
Matrix metalloproteinases contribute to the blood-brain barrier disruption during bacterial meningitis.
Ann Neurol
44:592-600[Web of Science][Medline].
-
Ploplis VA,
Carmeliet P,
Vazirzadeh S,
Van Vlaenderen I,
Moons L,
Plow EF,
Collen D
(1995)
Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice.
Circulation
92:2585-2593[Abstract/Free Full Text].
-
Preston E,
Sutherland G,
Finsten A
(1993)
Three openings of the blood-brain barrier produced by forebrain ischemia in the rat.
Neurosci Lett
149:75-78[Medline].
-
Qian Z,
Gilbert ME,
Colicos MA,
Kandel ER,
Kuhl D
(1993)
Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling an long-term potentiation.
Nature
361:453-457[Medline].
-
Rapaport S,
Thompson H
(1975)
Osmotic opening of the blood-brain barrier in the monkey without associated neurological deficits.
Science
180:971.
-
Roelcke U,
Radu EW,
von Ammon K,
Hausmann O,
Maguire RP,
Leenders KL
(1995)
Alteration of blood-brain barrier in human brain tumors: comparison of [18F]fluorodeoxyglucose, [11C]methionine and rubidium-82 using PET.
J Neurol Sci
132:20-27[Medline].
-
Ruth RE
(1986)
Extravasated protein as a cause of limbic seizure-induced brain damage: an evaluation using kainic acid.
Adv Exp Med Biol
203:211-221[Medline].
-
Ruth RE,
Feinerman GS
(1988)
Foreign and endogenous serum protein extravasation during harmaline tremors or kainic acid seizures in the rat: a comparison.
Acta Neuropathol
76:380-387[Medline].
-
Saija A,
Princi P,
Pisani A,
Santoro G,
De Pasquale R,
Massi M,
Costa G
(1992)
Blood-brain barrier dysfunctions following systemic injection of kainic acid in the rat.
Life Sci
51:467-477[Web of Science][Medline].
-
Sappino A-P,
Madani R,
Huarte J,
Belin D,
Kiss JZ,
Wohlwend A,
Vassalli J-D
(1993)
Extracellular proteolysis in the adult murine brain.
J Clin Invest
92:679-685.
-
Seitelberger F,
Lassmann H,
Hornykiewicz O
(1990)
Some mechanisms of brain edema studied in a kainic acid model.
Acta Neurobiol Exp
50:263-267[Medline].
-
Shoulson I
(1998)
Experimental therapeutics of neurodegenerative disorders: unmet needs.
Science
282:1072-1074[Abstract/Free Full Text].
-
Steinhauser C,
Gallo V
(1996)
News on glutamate receptors in glial cells.
Trends Neurosci
19:339-345[Web of Science][Medline].
-
Strickland S,
Gualandris A,
Rogove AD,
Tsirka SE
(1996)
Extracellular proteases in neuronal function and degeneration.
Cold Spring Harb Symp Quant Biol
61:739-745[Abstract/Free Full Text].
-
Strosznajder J,
Foudin L,
Tang W,
Sun GY
(1983)
Serum albumin washing specifically enhances arachidonate incorporation into synaptosomal phosphatidylinositols.
J Neurochem
40:84-90[Medline].
-
Ting P,
Masaoka H,
Kuroiwa T,
Wagner H,
Fenton I,
Klatzo I
(1986)
Influence of blood-brain barrier opening to proteins on development of post-ischaemic brain injury.
Neurol Res
8:146-151[Medline].
-
Tsirka SE,
Gualandris A,
Amaral DG,
Strickland S
(1995)
Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator.
Nature
377:340-344[Medline].
-
Tsirka SE,
Rogove AD,
Bugge TH,
Degen JL,
Strickland S
(1997)
An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus.
J Neurosci
17:543-552[Abstract/Free Full Text].
-
Vassalli JD,
Belin D
(1987)
Amiloride selectively inhibits the urokinase-type plasminogen activator.
FEBS Lett
214:187-191[Web of Science][Medline].
-
Wagner S,
Tagaya M,
Koziol JA,
Quaranta V,
del Zoppo GJ
(1997)
Rapid disruption of an astrocyte interaction with the extracellular matrix mediated by integrin alpha 6 beta 4 during focal cerebral ischemia/reperfusion.
Stroke
28:858-865[Abstract/Free Full Text].
-
Wahl M,
Unterberg A,
Baethmann A,
Schilling L
(1990)
Mediators of vasogenic brain edema.
J Basic Clin Physiol Pharmacol
1:221-233[Medline].
-
Wang YF,
Tsirka SE,
Strickland S,
Stieg PE,
Soriano SG,
Lipton SA
(1998)
Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice.
Nat Med
4:228-231[Web of Science][Medline].
Copyright © 1999 Society for Neuroscience 0270-6474/99/19229813-08$05.00/0
This article has been cited by other articles:

|
 |

|
 |
 
Z.-L. Chen, H. Yu, W.-M. Yu, R. Pawlak, and S. Strickland
Proteolytic fragments of laminin promote excitotoxic neurodegeneration by up-regulation of the KA1 subunit of the kainate receptor
J. Cell Biol.,
December 29, 2008;
183(7):
1299 - 1313.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. P. Lopez-Atalaya, B. D. Roussel, C. Ali, E. Maubert, K.-U. Petersen, V. Berezowski, R. Cecchelli, C. Orset, and D. Vivien
Recombinant Desmodus rotundus Salivary Plasminogen Activator Crosses the Blood-Brain Barrier Through a Low-Density Lipoprotein Receptor-Related Protein-Dependent Mechanism Without Exerting Neurotoxic Effects
Stroke,
March 1, 2007;
38(3):
1036 - 1043.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. R. Parathath, S. Parathath, and S. E. Tsirka
Nitric oxide mediates neurodegeneration and breakdown of the blood-brain barrier in tPA-dependent excitotoxic injury in mice
J. Cell Sci.,
January 15, 2006;
119(2):
339 - 349.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Benchenane, V. Berezowski, C. Ali, M. Fernandez-Monreal, J. P. Lopez-Atalaya, J. Brillault, J. Chuquet, A. Nouvelot, E. T. MacKenzie, G. Bu, et al.
Tissue-Type Plasminogen Activator Crosses the Intact Blood-Brain Barrier by Low-Density Lipoprotein Receptor-Related Protein-Mediated Transcytosis
Circulation,
May 3, 2005;
111(17):
2241 - 2249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. S. Heinemann, G. Korza, and J. Ozols
A Plasminogen-like Protein Selectively Degrades Stearoyl-CoA Desaturase in Liver Microsomes
J. Biol. Chem.,
October 31, 2003;
278(44):
42966 - 42975.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z.-L. Chen, J. A. Indyk, and S. Strickland
The Hippocampal Laminin Matrix Is Dynamic and Critical for Neuronal Survival
Mol. Biol. Cell,
July 1, 2003;
14(7):
2665 - 2676.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. T. Liberatore, A. Samson, C. Bladin, W.-D. Schleuning, and R. L. Medcalf
Vampire Bat Salivary Plasminogen Activator (Desmoteplase): A Unique Fibrinolytic Enzyme That Does Not Promote Neurodegeneration
Stroke,
February 1, 2003;
34(2):
537 - 543.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Xue and M. R. Del Bigio
Acute Tissue Damage After Injections of Thrombin and Plasmin into Rat Striatum
Stroke,
September 1, 2001;
32(9):
2164 - 2169.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. H. Yang, P. Carmeliet, and J. A. Hamilton
Tissue-Type Plasminogen Activator Deficiency Exacerbates Arthritis
J. Immunol.,
July 15, 2001;
167(2):
1047 - 1052.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Akassoglou, K. W. Kombrinck, J. L. Degen, and S. Strickland
Tissue Plasminogen Activator-Mediated Fibrinolysis Protects against Axonal Degeneration and Demyelination after Sciatic Nerve Injury
J. Cell Biol.,
May 29, 2000;
149(5):
1157 - 1166.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|